Abe N, Tanaka K, Kanaoka K, Egawa M, Watanabe I, Hirai S
Nihon Yakurigaku Zasshi. 1983 May;81(5):431-40.
Effects of piroxicam on allergic inflammation were investigated with allergic air pouch inflammation and antigen-induced arthritis in rats. In allergic air pouch inflammation, piroxicam exerted a dose-dependent inhibition (1-10 mg/kg, p.o.) of the exudate production, the migration of leukocytes and the release of lysosomal enzyme into the exudate; and its potency was superior to that of indomethacin and equivalent to that observed with prednisolone. In contrast with this, the suppressive effect of piroxicam on non-allergic air pouch inflammation was as weak as indomethacin. Prednisolone showed a similar effect on both types of air pouch inflammation. In antigen-induced arthritis, piroxicam showed a dose-dependent (0.3-3 mg/kg, p.o.) inhibitory effect on knee joint swelling and an improving action on the functional disorder of the inflamed joint. On this model, piroxicam was 3 to 4 times more active than both indomethacin and prednisolone. In non-allergic joint inflammation induced with croton oil in rats, however, the anti-inflammatory potency of piroxicam was almost equal to those of indomethacin and prednisolone. Piroxicam showed more potent inhibition than indomethacin on heterologous passive cutaneous anaphylaxis in rats, but showed only a slight inhibition on the increased vascular permeability caused by histamine and bradykinin. Piroxicam had no influence upon the plaque-forming cell response and the delayed hypersensitivity reaction in mice; furthermore, the hemolytic activity of complement in guinea-pig serum was scarcely affected by piroxicam in vitro. These results indicate that piroxicam possesses prominent efficiency on allergic inflammation and may function on several activities of inflammatory cells.
通过大鼠过敏性气囊炎症和抗原诱导性关节炎模型,研究了吡罗昔康对过敏性炎症的影响。在过敏性气囊炎症模型中,吡罗昔康(1 - 10毫克/千克,口服)对渗出物产生、白细胞迁移以及溶酶体酶释放到渗出物中均有剂量依赖性抑制作用;其效力优于吲哚美辛,与泼尼松龙相当。与此相反,吡罗昔康对非过敏性气囊炎症的抑制作用与吲哚美辛一样弱。泼尼松龙对两种类型的气囊炎症均有类似作用。在抗原诱导性关节炎模型中,吡罗昔康(0.3 - 3毫克/千克,口服)对膝关节肿胀有剂量依赖性抑制作用,并对炎症关节的功能障碍有改善作用。在该模型中,吡罗昔康的活性比吲哚美辛和泼尼松龙高3至4倍。然而,在大鼠巴豆油诱导的非过敏性关节炎症中,吡罗昔康的抗炎效力与吲哚美辛和泼尼松龙几乎相当。吡罗昔康对大鼠异种被动皮肤过敏反应的抑制作用比吲哚美辛更强,但对组胺和缓激肽引起的血管通透性增加仅有轻微抑制作用。吡罗昔康对小鼠的空斑形成细胞反应和迟发型超敏反应没有影响;此外,在体外,吡罗昔康对豚鼠血清中补体的溶血活性几乎没有影响。这些结果表明,吡罗昔康对过敏性炎症具有显著疗效,可能作用于炎症细胞的多种活性。